Alcohol Use Disorder Treatments - Disulfiram and Naltrexone
Alcohol use disorder (AUD) affects an estimated 283 million adults worldwide according to the World Health Organization, contributing to over 3 million deaths annually and a vast burden of cardiovascular disease, liver disease, cancer, accidents, mental illness, and family/social harm. Despite this scale, AUD remains under-treated — only a small fraction of those who could benefit receive evidence-based pharmacotherapy. This catalogue offers FDA-approved medications proven to support sustained recovery alongside counselling and behavioural support.
Modern alcohol use disorder treatment combines behavioural therapy (cognitive-behavioural therapy, motivational enhancement, mutual support groups like AA / SMART Recovery / community programmes) with medication-assisted treatment (MAT). Three medications are particularly well-evidenced: disulfiram (Antabuse / Carnotol) works through aversive conditioning; naltrexone (Lodonak / Nodict) reduces cravings and rewarding effects; acamprosate stabilises post-acute withdrawal. Each has specific indications, contraindications, and patient-fit profiles.
Choosing the right approach depends on severity of AUD, treatment goals (abstinence vs. moderation), motivation, prior treatment experience, comorbid conditions, and individual values. Increasingly, treatment focuses on harm reduction and reduced heavy drinking days rather than insisting on lifelong total abstinence as the only acceptable goal — particularly with naltrexone-based approaches like the Sinclair method. Whatever the goal, professional support substantially improves outcomes.
🥧 Conditions This Category Treats
Alcohol use disorder spans a spectrum from mild (2-3 of 11 DSM-5 criteria) through moderate (4-5 criteria) to severe (6+ criteria). Criteria include drinking more or longer than intended, unsuccessful attempts to cut down, time spent obtaining/using/recovering from alcohol, craving, failure to fulfil roles, social/interpersonal problems, reduced important activities, hazardous use, continued use despite physical/psychological problems, tolerance, and withdrawal. Mild AUD may respond to brief intervention and counselling alone; moderate-to-severe AUD benefits substantially from pharmacotherapy alongside behavioural support.
Beyond pure AUD, this category supports recovery from acute alcohol withdrawal (initial management typically with benzodiazepines under medical supervision, then long-term anti-craving therapy), relapse prevention after detoxification or rehab, and reduction of heavy drinking in patients not pursuing total abstinence. Concurrent management of alcohol-related medical complications (liver disease, cardiovascular disease, depression, anxiety, vitamin deficiencies) is integral to comprehensive care.
Co-occurring opioid use disorder can also be addressed with naltrexone, which blocks both opioid and alcohol-related receptors. Patients with both conditions need careful planning — naltrexone cannot be used in active opioid use because of precipitated withdrawal. Depression, anxiety, and PTSD commonly co-occur with AUD; treating these conditions concurrently is essential for sustained recovery.
💊 How Modern Alcohol Use Disorder Treatment Works
Disulfiram (Antabuse, Carnotol) irreversibly inhibits aldehyde dehydrogenase, the enzyme that processes acetaldehyde — the toxic intermediate in alcohol metabolism. Drinking alcohol while on disulfiram causes acetaldehyde accumulation, producing intensely unpleasant symptoms: facial flushing, throbbing headache, nausea, vomiting, palpitations, breathlessness, anxiety, chest pain. The aversive experience deters drinking. Disulfiram works through knowledge of consequences rather than reducing craving directly — it is most effective in highly motivated patients with reliable supervised administration.
Standard disulfiram course: 500 mg daily for 1-2 weeks then 250 mg daily maintenance. The reaction can occur with any alcohol exposure including some mouthwashes, cooking wine, certain cough syrups, and topical preparations — patients must be educated about hidden alcohol sources. Disulfiram remains active for 2 weeks after stopping. Reactions can be severe and rarely life-threatening — contraindicated in severe cardiac or hepatic disease. The drug also has a slower-acting interaction with metronidazole (psychosis risk) and isoniazid.
Naltrexone (Lodonak, Nodict) is an opioid receptor antagonist that blocks the rewarding effects of alcohol mediated by endogenous opioid release. Result: reduced craving, fewer heavy drinking days, and improved chance of maintained abstinence in motivated patients. Standard dose: 50 mg daily oral, or 380 mg monthly intramuscular extended-release. The Sinclair method uses naltrexone 1-2 hours before any drinking, gradually extinguishing alcohol response over months — useful for patients pursuing moderation rather than total abstinence. Side effects (nausea, headache, fatigue) are usually mild and transient. Contraindicated in active opioid use (precipitates withdrawal). Liver function monitoring at baseline and periodically. Lodonak (3 mg low-dose naltrexone) has gained interest for off-label uses in chronic pain and inflammation, distinct from AUD treatment.
💊 Drug Classes in This Category
| Class | Best For | Examples |
|---|---|---|
| Aversion therapy (ALDH inhibitor) | Highly motivated AUD patients seeking total abstinence; supervised administration | Antabuse (disulfiram 500mg), Carnotol (disulfiram 250mg) |
| Opioid receptor antagonist (50mg) | Standard anti-craving therapy in AUD; Sinclair method; reduced heavy drinking | Nodict (naltrexone 50mg) |
| Low-dose naltrexone (LDN) | Off-label uses in chronic pain, autoimmune; supplementary AUD use | Lodonak (naltrexone 3mg) |
✅ How to Choose
- 🍻 Highly motivated patient seeking absolute abstinence, reliable supervised administration available → Antabuse / Carnotol (disulfiram) 250-500 mg daily; educate about hidden alcohol sources.
- 🎀 Patient pursuing moderation or total abstinence with cravings as main issue → Nodict (naltrexone) 50 mg daily; review at 1 month for tolerance and response.
- 🍷 Patient interested in Sinclair method (drink less while taking naltrexone) → Nodict 50 mg taken 1-2 hours before any drinking; expect gradual extinguishment over weeks to months.
- 💤 Severe AUD with multiple prior relapses → consider extended-release injectable naltrexone (Vivitrol) for adherence assurance; integrated mental health care; intensive behavioural support.
- 💉 Concurrent opioid use disorder → naltrexone can address both after complete opioid detoxification; avoid disulfiram complications.
- 🥩 Active hepatitis or cirrhosis → avoid disulfiram; naltrexone with careful LFT monitoring; specialist input.
❓ Frequently Asked Questions about AUD Treatment
How effective is medication for alcohol use disorder?
Naltrexone reduces heavy drinking days by approximately 25-40% compared to placebo when combined with counselling. Disulfiram is effective in highly motivated patients with supervised administration. Combined pharmacotherapy + counselling roughly doubles long-term abstinence and reduced-drinking rates. These numbers are similar to medication efficacy for other chronic conditions like depression.
What is the Sinclair method?
The Sinclair method uses naltrexone before drinking rather than for abstinence support. Taking naltrexone 1-2 hours before any alcohol blocks the reinforcing effect, gradually extinguishing the conditioned response over months. Goal is reduced or eliminated drinking through behavioural extinction rather than willpower. Best for patients who are not seeking strict abstinence and can reliably take medication before drinking.
Can I drink alcohol while on naltrexone?
You can — naltrexone does not produce aversive reactions like disulfiram. It simply reduces the rewarding effect. Many patients report alcohol "loses its appeal" or "doesn't do anything anymore". For Sinclair method approach this is intended. For abstinence-focused treatment, the absence of reward helps maintain not drinking but does not punish slips.
Why do I need counselling alongside medication?
Medications address the neurobiology of addiction (cravings, reward, withdrawal). Counselling addresses the psychological, social, and behavioural components (triggers, coping skills, relationships, life skills, mental health). Both are needed for sustained recovery. The combination is roughly twice as effective as either alone.
Will I become dependent on naltrexone?
No. Naltrexone does not produce euphoria, dependence, tolerance, or withdrawal. It blocks opioid receptors without activating them. You can stop without consequences (though craving and drinking risk may return). It is much safer in this respect than addictive medications.
Should I tell family or friends I am on these medications?
This is your decision but disclosure often helps. Supervised disulfiram administration by a trusted family member dramatically improves adherence and effectiveness. Family and friend support more broadly is associated with better long-term recovery outcomes. AUD treatment is medical care — not something to hide.
🩺 When to See a Healthcare Provider
AUD treatment is most successful with multidisciplinary support: primary care or addiction medicine physician for prescribing and monitoring, counsellor or therapist for behavioural support, possibly group support (AA, SMART Recovery, others). Acute alcohol withdrawal can be life-threatening — severe withdrawal with shakes, seizures, autonomic instability, or delirium tremens requires medical management, often in hospital. Long-term anti-craving therapy is started after withdrawal management.
Comprehensive care addresses co-occurring conditions: depression and anxiety (very common in AUD; treat concurrently), liver disease, cardiovascular disease, nutritional deficiencies (especially thiamine and folate), and sleep disorders. Many alcohol-related conditions improve dramatically with sustained abstinence. Tell every prescriber about anti-craving medications — naltrexone affects pain management; disulfiram has multiple drug interactions.